This Article Full Text Full Text (PDF) All Versions of this Article: 48/3/374    most recent 01.HYP.0000231662.77359.dev1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Leenen, F. H.H. Search for Related Content PubMed PubMed Citation Articles by Leenen, F. H.H. Related Collections Hypertension - basic studies Clinical Studies

(Hypertension. 2006;48:374.)
© 2006 American Heart Association, Inc.

Original Articles

Clinical Events in High-Risk Hypertensive Patients Randomly Assigned to Calcium Channel Blocker Versus Angiotensin-Converting Enzyme Inhibitor in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial

Frans H.H. Leenen; Chuke E. Nwachuku; Henry R. Black; William C. Cushman; Barry R. Davis; Lara M. Simpson; Michael H. Alderman; Steven A. Atlas; Jan N. Basile; Aloysius B. Cuyjet; Richard Dart; James V. Felicetta; Richard H. Grimm; L. Julian Haywood; Syed Z.A. Jafri; Michael A. Proschan; Udho Thadani; Paul K. Whelton; Jackson T. Wright for the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) Collaborative Research Group

From the University of Ottawa Heart Institute (F.H.H.L.), Ottawa, Ontario, Canada; National Heart, Lung, and Blood Institute (M.A.P., C.E.N.), Bethesda, Md; Rush-Presbyterian-St. Luke’s Medical Center (H.R.B.), Chicago, Ill; Memphis Veterans Affairs Medical Center (W.C.C.), Tenn; University of Texas Health Science Center School of Public Health (B.R.D., L.M.S.), Houston; Albert Einstein College of Medicine (M.H.A.), Bronx, NY; Bronx Veterans Affairs Medical Center (S.A.A.), NY; Charleston Veterans Affairs Medical Center (J.N.B.), SC; New Jersey Medical School (A.B.C.), Newark; Marshfield Clinic (R.D.), Marshfield, Wis; Carl T. Hayden Veterans Affairs Medical Center (J.V.F.), Phoenix, Ariz; Berman Center for Outcomes and Clinical Research (R.H.G.), Minneapolis, Minn; Los Angeles County–University of Southern California Medical Center (L.J.H.); Fargo Veterans Affairs Medical Center (S.Z.A.J.), ND; University of Oklahoma Health Sciences Center and Veterans Affairs Medical Center (U.T.), Oklahoma City; Tulane University Health Sciences Center (P.K.W.), New Orleans, La; University Hospitals of Cleveland (J.T.W.), Ohio.

Correspondence to Frans H.H. Leenen, Hypertension Unit, University of Ottawa Heart Institute, H-360, 40 Ruskin St, Ottawa, Ontario K1Y 4W7, Canada. E-mail fleenen{at}ottawaheart.ca

The Antihypertensive and Lipid-Lowering treatment to prevent Heart Attack Trial (ALLHAT) provides a unique opportunity to compare the long-term relative safety and efficacy of angiotensin-converting enzyme inhibitor and calcium channel blocker–initiated therapy in older hypertensive individuals. Patients were randomized to amlodipine (n=9048) or lisinopril (n=9054). The primary outcome was combined fatal coronary heart disease or nonfatal myocardial infarction, analyzed by intention-to-treat. Secondary outcomes included all-cause mortality, stroke, combined cardiovascular disease (CVD), end-stage renal disease (ESRD), cancer, and gastrointestinal bleeding. Mean follow-up was 4.9 years. Blood pressure control was similar in nonblacks, but not in blacks. No significant differences were found between treatment groups for the primary outcome, all-cause mortality, ESRD, or cancer. Stroke rates were higher on lisinopril in blacks (RR=1.51, 95% CI 1.22 to 1.86) but not in nonblacks (RR=1.07, 95% CI 0.89 to 1.28), and in women (RR=1.45, 95% CI 1.17 to 1.79), but not in men (RR=1.10, 95% CI 0.92 to 1.31). Rates of combined CVD were higher (RR=1.06, 95% CI 1.00 to 1.12) because of higher rates for strokes, peripheral arterial disease, and angina, which were partly offset by lower rates for heart failure (RR=0.87, 95% CI 0.78 to 0.96) on lisinopril compared with amlodipine. Gastrointestinal bleeds and angioedema were higher on lisinopril. Patients with and without baseline coronary heart disease showed similar outcome patterns. We conclude that in hypertensive patients, the risks for coronary events are similar, but for stroke, combined CVD, gastrointestinal bleeding, and angioedema are higher and for heart failure are lower for lisinopril-based compared with amlodipine-based therapy. Some, but not all, of these differences may be explained by less effective blood pressure control in the lisinopril arm.

Key Words: antihypertensive therapy • hypertension, detection and control • calcium channel blockers • angiotensin-converting enzyme • cardiovascular diseases • stroke • heart failure

This article has been cited by other articles:

				J. T. Wright Jr, J. L. Probstfield, W. C. Cushman, S. L. Pressel, J. A. Cutler, B. R. Davis, P. T. Einhorn, M. Rahman, P. K. Whelton, C. E. Ford, et al. ALLHAT Findings Revisited in the Context of Subsequent Analyses, Other Trials, and Meta-analyses Arch Intern Med, May 11, 2009; 169(9): 832 - 842. [Abstract] [Full Text] [PDF]

				D. R. Miller, S. A. Oliveria, D. R. Berlowitz, B. G. Fincke, P. Stang, and D. E. Lillienfeld Angioedema Incidence in US Veterans Initiating Angiotensin-Converting Enzyme Inhibitors Hypertension, June 1, 2008; 51(6): 1624 - 1630. [Abstract] [Full Text] [PDF]

				J.-G. Wang, Y. Li, S. S. Franklin, and M. Safar Prevention of Stroke and Myocardial Infarction by Amlodipine and Angiotensin Receptor Blockers: A Quantitative Overview Hypertension, July 1, 2007; 50(1): 181 - 188. [Abstract] [Full Text] [PDF]

				CCB vs. ACE Inhibitor in High-Risk Hypertension Journal Watch Cardiology, September 27, 2006; 2006(927): 5 - 5. [Full Text]

				F. H. Messerli and J. A. Staessen Amlodipine Better Than Lisinopril?: How One Randomized Clinical Trial Ended Fallacies From Observational Studies Hypertension, September 1, 2006; 48(3): 359 - 361. [Full Text] [PDF]